|
Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib. |
|
|
|
Consulting or Advisory Role - Celgene; MSD; Novartis; Roche; Takeda |
Research Funding - Bayer (Inst); Celgene (Inst); Janssen-Cilag (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; MSD; Pfizer; SERVIER |
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Celgene; Lilly; Novartis; Roche; Sandoz; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Hexal; Johnson & Johnson; Novartis; Roche |
Research Funding - AstraZeneca; Bayer; Celgene; Gilead Sciences; Johnson & Johnson; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Honoraria - Bristol-Myers Squibb; Gilead Sciences; Janssen; MSD; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Janssen; MSD; SERVIER |
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen; MSD; SERVIER |
|
|
Consulting or Advisory Role - Bayer; Celgene; Gilead Sciences; Janssen; Novartis; Roche; Sandoz |
Speakers' Bureau - Bayer; Celgene; Gilead Sciences; Janssen; Roche |
Research Funding - Celgene (Inst); Janssen (Inst); Mundipharma (Inst); Roche |